RCEL on XNAS, Health Care, Avita Medical, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue rose 53% and the stock is up 307% in a year, but it lost $36.1M over 12 months.
BadFree cash flow was minus $19.3M over the last 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $26.1M, net loss $6.2M.
31 Dec 2021RevenueNet incomeNet losstallest bar $26.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$26.1M
-$6.2M
30 Jun 2026
$21.7M
-$7.7M
31 Mar 2026
$19.3M
-$10.6M
31 Dec 2025
$17.6M
-$11.6M
30 Sep 2025
$17.1M
-$13.2M
30 Jun 2025
$18.4M
-$9.9M
31 Mar 2025
$18.5M
-$13.9M
31 Dec 2024
$18.4M
-$11.6M
30 Sep 2024
$19.5M
-$16.2M
30 Jun 2024
$15.2M
-$15.4M
31 Mar 2024
$11.1M
-$18.7M
31 Dec 2023
$14.2M
-$7.1M
30 Sep 2023
$13.6M
-$8.7M
30 Jun 2023
$11.8M
-$10.4M
31 Mar 2023
$10.6M
-$9.2M
31 Dec 2022
$9.5M
-$5.4M
30 Sep 2022
$9.1M
-$5.6M
30 Jun 2022
$8.3M
-$6.3M
31 Mar 2022
$7.5M
-$9.5M
31 Dec 2021
$6.9M
-$8.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$84.7M
$72.4M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+17%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$36.1M
-$48.6M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.17
-$1.81
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
82.4%
83.7%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-33.9%
-58.1%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-42.7%
-67.1%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$19.3M
-$37.1M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$10.5M
$23.3M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$45.5M
$42.4M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$35.0M
$19.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
5.8
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
6.2
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+53%
$26.1M vs $17.1M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+21%
88 13F filers vs 73
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
29%
9.3M shares held by 13F filers (30 Sep 2026) of 31.4M outstanding (3 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
8.9%
2.8M shares sold short (30 Oct 2026) of 31.4M outstanding (3 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
6.1
2.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-1.0%
2.8M shares sold short in the report before, 2.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
49%
49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$13.3M
the 12 months before: $359K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$30K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
8
8 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
2.3×
8 articles in the last 7 days; its usual week has 3.5.
Unusual now sharp changes in the last 90 days, compared with its own past
Revenue $25.9M, 1.5× a year earlier
Price $15.62 on 20 Nov 2026, +307% over 12 months (12-month range $3.27 to $17.65)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $227K in the last 12 months (the 12 months before: $345K).Revenue per quarter. Revenue $26.1M in the latest quarter, +53% on a year earlier.Capital spending per quarter. Capital spending $111K in the latest quarter, -88% on a year earlier.Institutional holders (13F filers). 88 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.Federal obligations. Federal obligations: $13.2M published in the last 12 months, +3455% on the 12 months before.Lobbying spend. Lobbying spend: $30K published in the last 12 months, +100% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, workers in warn layoff notices.
Reported lobbying spend: $15K in Q1 2026, $15K in Q4 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Mar 2026
Ended
Jeffrey J. Kimbell & Associates, Inc.for Avita Medical, Inc.
issues related to therapeutic wound care; issues related to reimbursement for wound care treatmentsHealth issues, Medicare/Medicaid
Two or more unrelated kinds of records unusual within 30 days
31 Aug 2021confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Avita Medical(RCEL): had 1.6M shares sold short in the 30 Jul 2021 report, 14× the same report last year, while it reported revenue of $10.3M for the quarter ended 30 Jun 2021, 2.7× the same quarter last year. Two unrelated kinds of activity within 14 days.
Short interest and volume: Short interest spike, became public on 11 Aug 2021
Financials: Quarterly revenue change, became public on 31 Aug 2021
The 30 Jul 2021 report against the 24 reports before it.
this reportearliernormal: 413KSee the evidence (2 changes)
Short interest and volume: Short interest spike became public on 11 Aug 2021
Avita Medical had 1.6M shares sold short in the 30 Jul 2021 report, 14× the same report last year.
This period
1.6M (the 30 Jul 2021 report)
Normal report (median of 24 earlier)
413K
Typical spread (median absolute deviation)
196K
How far from its usual level
+4.2
Same report last year
119K
History used
654 days
the 30 Jul 2021 report24 earlier reportsnormal: 413K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 31 Aug 2021
Avita Medical reported revenue of $10.3M for the quarter ended 30 Jun 2021, 2.7× the same quarter last year.
This period
$10.3M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$3.9M
Typical spread (median absolute deviation)
$905K
How far from its usual level
+4.8
Same quarter last year
$3.9M
History used
1,004 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $3.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
10 Nov 2026Financials change
reported revenue of $25.9M for the quarter ended 30 Sep 2026, 1.5× the same quarter last year.
Same quarter last year: $16.9M; its normal quarter is $18.3M.
See the evidence
This period
$25.9M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$18.3M
Typical spread (median absolute deviation)
$816K
How far from its usual level
+4.2
Same quarter last year
$16.9M
History used
2,922 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $18.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 5.4M shares sold short in the 15 Aug 2025 report, 3.3× the same report last year.
Same report last year: 1.6M; its normal report is 1.8M.
See the evidence
This period
5.4M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
628K
How far from its usual level
+3.8
Same report last year
1.6M
History used
2,131 days
the 15 Aug 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.8M shares sold short in the 31 Jul 2025 report, 3.1× the same report last year.
Same report last year: 1.9M; its normal report is 1.8M.
See the evidence
This period
5.8M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
577K
How far from its usual level
+4.7
Same report last year
1.9M
History used
2,116 days
the 31 Jul 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.7M shares sold short in the 15 Jul 2025 report, 2.9× the same report last year.
Same report last year: 2.0M; its normal report is 1.8M.
See the evidence
This period
5.7M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
507K
How far from its usual level
+5.2
Same report last year
2.0M
History used
2,100 days
the 15 Jul 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.5M shares sold short in the 13 Jun 2025 report, 2.2× the same report last year.
Same report last year: 2.0M; its normal report is 1.8M.
See the evidence
This period
4.5M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
310K
How far from its usual level
+5.9
Same report last year
2.0M
History used
2,068 days
the 13 Jun 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.0M shares sold short in the 30 May 2025 report, 2.1× the same report last year.
Same report last year: 1.9M; its normal report is 1.8M.
See the evidence
This period
4.0M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.8M
Typical spread (median absolute deviation)
296K
How far from its usual level
+5.0
Same report last year
1.9M
History used
2,054 days
the 30 May 2025 report24 earlier reportsnormal: 1.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.7M shares sold short in the 15 May 2025 report, 2.2× the same report last year.
Same report last year: 1.7M; its normal report is 1.7M.
See the evidence
This period
3.7M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.7M
Typical spread (median absolute deviation)
242K
How far from its usual level
+5.5
Same report last year
1.7M
History used
2,039 days
the 15 May 2025 report24 earlier reportsnormal: 1.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 30 Apr 2025 report, 1.9× the same report last year.
Same report last year: 1.6M; its normal report is 1.6M.
See the evidence
This period
3.0M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
232K
How far from its usual level
+3.9
Same report last year
1.6M
History used
2,024 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 95 entries; narrow the window or the kind of data to see older ones.
Not listed: 124 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001762303
Ticker
RCEL
Domain
avitamedical.com
Hq location
CA|VALENCIA|91355 (1 unverified)
Lobbying client
avita medical
Name
AVITA Medical Americas, LLC, Avita Medical, Inc., Avita Therapeutics, Inc.
Uei
JY1HRCEKX2L4, T3NUKR3AAX45, YKFASYUPNGZ2
Wikidata
Q4828994
Wikipedia
Avita Medical
Federal lobbying disclosures (LDA)4 records, 23 data points5 Jan 2017 to 31 Mar 2026
SEC Form 13F institutional holdings338 data points30 Sep 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)142 records19 Dec 2018 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)611 data points30 Jun 2017 to 3 Nov 2026
SEC Form 4 insider transactions41 records, 152 data points21 Jul 2020 to 24 Aug 2026
FINRA short interest (twice monthly)507 data points15 Oct 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3588 data points1 Oct 2019 to 20 Nov 2026
USASpending.gov federal awards1 record, 69 data points20 Jun 2023 to 9 Jul 2026
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026